• New pilot medical insurance payments to prevent over diagnosis and over treatment.

• DRG is a payment based on a calculation by doctors, while DIP is based on utilising existing data to work out reasonable prices for medical procedures.

• Implementation challenging as many hospitals do not have electronic patient records.

• New, innovative medical devices not covered by DRG so presenting a major opportunity for multinationals.

• Filing of new patents strongly supported by the government, so more multinationals filing patents in China.

About InterChina

InterChina is a leading strategy and corporate finance boutique specialized in China. Healthcare is one of our core sectors of expertise with consultants and advisors dedicated to the space. Our multinational and Chinese clients choose to work with us because we provide real understanding, deliver practical results, and know how to get things done. We are a partner led firm and distinguish ourselves by the deep level of engagement partners have in client engagements.

Rick Woo
Principal, InterChina
Rick.Woo@InterChinaConsulting.com